#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Heavy menstrual bleeding Focal segmental glomerulosclerosis Rhabdoid tumour Neuromyelitis optica spectrum disorder Mantle cell lymphoma stage III Biliary cancer metastatic Alpha-1 antitrypsin deficiency Cutaneous lupus erythematosus Erythema multiforme Vitamin B12 deficiency Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome Sjogren's syndrome Lymphangioma Red blood cell abnormality Monogenic diabetes More trials…

    Learn about Rare Diseases

    Hyperoxaluria – Basic Information Pleomorphic leiomyosarcoma Hereditary angioedema – Diagnostics Lymphangioma – Diagnostics Optic glioma – Life with Disease Von Willebrand’s disease – Diagnostics Primary biliary cholangitis – Life with Disease Adrenogenital syndrome Inclusion body myositis – Basic Information Usher’s syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ANGIOTENSIN II Lutikizumab Astegolimab SAR444336 Rocatinlimab Modafinil Ag13909 Ganciclovir OLVEREMBATINIB Vidofludimus Calcium Dorzolamide Alectinib Hydrochloride TUVATEXIB Aminocaproic Acid Anastrozole Eftrenonacog Alfa Ozanimod Satralizumab Ucp2 Pioglitazone Hydrochloride More therapies…

    Learn about Your Condition

    Biopsy heart Chronic coronary syndrome Uveitis Metastatic glioma Carotid artery stenosis Overweight Plasma cell myeloma refractory Gaucher's disease type I Necrotising myositis Tuberculosis Immunosuppression Klinefelter's syndrome Plasma cell leukaemia Eye inflammation Axial spondyloarthritis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Deutsche Diabetes Forschungsgesellschaft e.V.

Deutsche Diabetes Forschungsgesellschaft e.V.

Ayyndewabl Hgydlgefx 6jy Bhzgd Dsgjmtqfljhw 4umdzg Gvvmcme

Want to learn more about this study or check if you can participate? Contact us.

  • N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

    Recruiting

    3 1
    Investigated Diseases:
    • Metabolic dysfunction-associated liver disease
    Investigated Drugs:
    • Ly3437943 Sodium
    • Tirzepatide
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study testing capsaicin patches compared to placebo for patients with painful diabetic nerve damage to assess effects on nerve symptoms and nerve fibers

    Recruiting

    2 1 1
    Investigated Diseases:
    • Diabetic neuropathy
    Investigated Drugs:
    • Capsaicin
    Germany

  • Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Cardiovascular disorder
    • Hypertension
    • Type 2 diabetes mellitus
    Investigated Drugs:
    • Bi 690517
    • Empagliflozin
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on Dapansutrile for Patients with Type 2 Diabetes Not Well Controlled on Standard Treatment

    Recruiting

    2 1
    Investigated Drugs:
    • Dapansutrile
    Belgium France Germany

  • Study on Dapagliflozin and Lifestyle Changes for Patients with Early Chronic Kidney Disease and Prediabetes

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dapagliflozin
    Germany

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!